Want to see ADIL full AI Analyst Report?
ADIL Stock Chart & Stats
$5.94
$0.10(3.73%)
At close: 4:00 PM EDT
$5.94
$0.10(3.73%)
Day’s Range― - ―
52-Week Range$1.31 - $10.76
Previous CloseN/A
Volume38.05K
Average Volume (3M)76.74K
Market Cap
$17.46M
Enterprise Value$45.46
Total Cash (Recent Filing)$28.71M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Nov 18, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.53
Shares Outstanding2,625,890
10 Day Avg. Volume61,823
30 Day Avg. Volume76,742
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.70
Price to Sales (P/S)0.00
P/FCF Ratio-0.57
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.32
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.50Price Target Upside43.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.04
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Minimal DebtEssentially no debt reduces refinancing and interest-rate exposure, preserving more flexibility for a clinical-stage company to allocate capital to development. This is a relative balance-sheet strength even though it does not offset the company’s negative equity and ongoing cash needs.
Expanded Pipeline And FinancingThe completed Azora acquisition adds a new development program, AT177, and access to up to $64 million in private-placement financing. That broader pipeline and committed capital could support early clinical milestones and extend the company’s ability to pursue its revised inflammatory-disease strategy.
Precision-Medicine StrategyADIL’s focus on patient segmentation using genetic and other biomarkers gives its lead program a precision-medicine orientation. If successfully executed, this approach can concentrate development on defined patient groups and create a more targeted clinical strategy for alcohol use disorder.
Bears Say
No Commercial RevenueThe absence of reported revenue confirms that ADIL remains dependent on clinical development rather than commercial product sales. Until a candidate is approved, partnered, or otherwise monetized, the business lacks recurring operating revenue to support research spending and corporate costs.
Heavy Losses And Cash BurnMaterially widened losses alongside negative operating and free cash flow show that ADIL is not yet self-funding. Continued burn increases reliance on external capital and can constrain development choices, while a sharp loss increase weakens the quality and durability of near-term financial performance.
Nasdaq Compliance RiskThe Nasdaq notice creates a durable financing and liquidity risk because failure to restore required equity or satisfy an approved plan could lead to suspension or delisting. A listing loss would reduce trading access and may complicate future capital raising for clinical programs.
Adial Pharmaceuticals News
ADIL FAQ
What was Adial Pharmaceuticals Inc’s price range in the past 12 months?
Adial Pharmaceuticals Inc lowest stock price was $1.31 and its highest was $10.76 in the past 12 months.
What is Adial Pharmaceuticals Inc’s market cap?
Adial Pharmaceuticals Inc’s market cap is $17.46M.
When is Adial Pharmaceuticals Inc’s upcoming earnings report date?
Adial Pharmaceuticals Inc’s upcoming earnings report date is Nov 18, 2026 which is in 69 days.
How were Adial Pharmaceuticals Inc’s earnings last quarter?
Adial Pharmaceuticals Inc released its earnings results on Aug 17, 2026. The company reported -$11.25 earnings per share for the quarter, missing the consensus estimate of -$1.032 by -$10.218.
Is Adial Pharmaceuticals Inc overvalued?
According to Wall Street analysts Adial Pharmaceuticals Inc’s price is currently Undervalued.
Does Adial Pharmaceuticals Inc pay dividends?
Adial Pharmaceuticals Inc does not currently pay dividends.
What is Adial Pharmaceuticals Inc’s EPS estimate?
Adial Pharmaceuticals Inc’s EPS estimate is -0.18.
How many shares outstanding does Adial Pharmaceuticals Inc have?
Adial Pharmaceuticals Inc has 2,625,890 shares outstanding.
What happened to Adial Pharmaceuticals Inc’s price movement after its last earnings report?
Adial Pharmaceuticals Inc reported an EPS of -$11.25 in its last earnings report, missing expectations of -$1.032. Following the earnings report the stock price went up 25.377%.
Which hedge fund is a major shareholder of Adial Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ADIL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Adial Pharmaceuticals Inc
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
ADIL Stock 12 Month Forecast
Average Price Target
$8.50
▲(43.10% Upside)
Technical Analysis
Galmed Pharmaceuticals
―
Kiora Pharmaceuticals
―
Matinas BioPharma
―
Alzamend Neuro
―
Calidi Biotherapeutics
―
Ownership Overview
30.11% Insiders
0.24% Mutual Funds
28.84% Other Institutional Investors
40.59% Public Companies and
Individual Investors